COMP <GO>
IMTX vs INBX // GROSS PROFIT MARGIN
Immatics N.V. (NASDAQ) VS. Inhibrx Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: IMTX 2
— INBX 0
■ METRIC PARITY
LAST: $7.31 (-0.54%) • MKT CAP: $1.09B
gross-margins
—
LAST: $73.65 (+0.49%) • MKT CAP: $1.08B
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMTX VS. INBX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMTX | INBX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -11.98% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.1 | 33.6 | +10.50 | IMTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.09B | $1.08B | $9.9M | IMTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMTX REV | INBX REV | IMTX GROSS % | INBX GROSS % | IMTX FCF | INBX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $1.3M | — | — | — | -$129.8M |
| FY 2024 | — | $200.0K | — | — | — | -$197.0M |
| FY 2023 | — | $1.8M | — | — | — | -$193.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMTX // BETA —
INBX // BETA —